胆钙化醇 *Sigma货号：C9756-5g/C9756-1

一般描述

胆钙化醇作为一种激素前体，因为它需要两个代谢阶段：首先是 25-羟胆钙化醇；然后加入 1α，25-二羟胆钙化醇
一个单位（U.S.P. 或国际）定义为 USP 维生素 D 参考标准中含有 0.025 μg 维生素D3 的活性
胆钙化醇来源于饮食或皮肤接触紫外线
口服维生素 D3 容易被吸收，并储存在脂肪组织中
[1] 应用 Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.: This study delves into the significant roles of cholecalciferol in modulating the renal-bone axis, inflammatory responses, and iron metabolism in elderly patients with renal impairment. Through vitamin D supplementation, researchers observed pivotal changes that could guide future therapeutic strategies (Christodoulou M et al., 2024).
Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study.: This clinical trial assesses the efficacy of cholecalciferol in improving the health outcomes of patients with multiple sclerosis. The use of cholecalciferol potentially enhances neurological function and reduces disease progression, illustrating its vital role in neurodegenerative disease management (Maghbooli Z et al., 2024).
Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.: This pivotal research links cholecalciferol to the reduction of COVID-19 severity through its regulatory effects on the NLRP3 inflammasome pathway. The findings underscore the potential of vitamin D as a modulatory agent in the immune response against viral infections (Khalil B et al., 2024).
Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals.: This randomized controlled trial explores how cholecalciferol supplementation can affect cardiovascular and autonomic functions in obese or overweight patients, providing insights into its benefits beyond bone health and into cardiovascular regulation (Faria ACC et al., 2024).